AlphaLens

TERMINAL

ANALYSIS

Heatmap Stock Lists AlphaBrain Compare Track Record News Rumor Radar Calendar Macro Leaderboard ETF X-Ray Learn

MY SPACE

Dashboard Watchlist Portfolio Achievements Settings

QUICK ACCESS

AAPLApple MSFTMicrosoft NVDANVIDIA GOOGLAlphabet AMZNAmazon TSLATesla

Home Screener Watchlist Account

v12

TICKER Dashboard Screener Macro

UTC ●

LOADING MARKET DATA… │ UTC ●

Loading page…

Screener·Stocks·Lists·Heatmap·Top Picks·Deep-Dives·AlphaBrain·Track Record·Accountability·News·Rumor Radar·Compare·Learn·Free SEC Filings·Pricing·FAQ·Terms·Privacy

AlphaLens provides algorithmic financial data and pre-computed AI analysis for educational and informational purposes only. AlphaScore™, TSI™, EQS™, AlphaMomentum™, Close-vs-Gap Pressure, CER™, Volatility Regime™, Earnings Execution™, Macro Regime Detector™, Portfolio Health Engine™, and Similarity Engine™ are proprietary mathematical algorithms. No output constitutes investment advice or a guarantee of future performance. Conduct independent research. Consult a licensed financial advisor.

Penumbra, Inc. (PEN)

Penumbra, Inc.

Healthcare

$319.40

+0.59%

nightly snapshot · 10/11/2026

ALPHASCORE™ · B · Watch

ALPHASCORE

/ 100

WATCH

▲ 0 · 30D

KEY FUNDAMENTALS

P/E78.1

ROE12.4%

NET MARGIN12.7%

GROSS MARGIN67.1%

MKT CAP$12.58B

loading full analysis…

DAILY BRIEF

Penumbra, Inc. is assigned an AlphaScore of 64/100 in the healthcare sector. Fundamentals include a net margin of 12.66% and a gross margin of 67.14% as of October 11, 2026. A clear strength is its robust revenue growth of 17.50%, indicating strong market demand. A primary risk factor is its high price-to-earnings ratio of 78.09, suggesting an elevated valuation relative to current earnings.

Written 11/10/2026, 00:40:23 UTC · Snapshot 11/10/2026